Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Smoothie Factory supports Chronic Disease Fund’s mission with holiday fundraising program

More than 14-million Americans, with chronic or life altering diseases and cancer, can’t afford the medication they need because of the high out-of-pocket costs associated with their insurance coverage. That’s why the Chronic Disease Fund, a nonprofit organization, provides financial help to seriously ill Americans so they can get the medications they need to live without the fear of debt.

25 Nov 2009

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

Canadians with chronic neck and back pain now have access to top spinal care

Canadians suffering from chronic and severe neck and back pain now have access to the top spinal care available. Spinal heath expert, Dr. Ron Nusbaum, has launched Back Clinics of Canada, a state-of-the-art facility that focuses on educating patients on the importance of spinal health and offering cutting-edge care that can bring an end to back pain.

25 Nov 2009

$Current, older generation is more prone to hip and pelvic fractures$

Current, older generation is more prone to hip and pelvic fractures

Stover and his partner, Dr. Hobie Summers, use leading edge technologies to treat serious and sometimes life-threatening orthopedic conditions such as pelvic fractures, broken legs, foot and ankle injuries and dislocations. They also treat patients who have experienced multiple traumatic injuries.

24 Nov 2009

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Ohr Pharmaceutical Inc. is developing OHR/AVR118 for treatment of cachexia based on technology acquired earlier this year from Advanced Viral Research Corp. OHR/AVR118 has shown excellent therapeutic efficacy and safety in human clinical trials in over 100 patients with applications for cachexia in Cancer and AIDS patients, as well as Rheumatoid Arthritis.

24 Nov 2009

Health Heritage: New website for maintaining family's health history

A team of researchers at the University of Virginia received funding from the National Cancer Institute, an agency of the National Institutes of Health, to enhance a Web site called Health Heritage®. This site will enable family members to enter their family medical histories so that other family members and their health care professionals can use this information while dealing with medical issues.

24 Nov 2009

Vitamin D: A multi-purpose nutrient for overall health

A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic."

24 Nov 2009

Morbid obesity among people with diabetes is increasing at a very alarming rate, says kidney expert

A Loyola University Health System study has found that one out of five Type 2 diabetics is morbidly obese -- approximately 100 pounds or more overweight.

23 Nov 2009

NAPRELAN Dose Card launched by Victory Pharma

Victory Pharma, Inc. ("Victory") announced today the launch of NAPRELAN® Dose Card, a further extension of Victory's NAPRELAN franchise.

23 Nov 2009

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.

20 Nov 2009

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

Ligand Pharmaceuticals Incorporated announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December.

19 Nov 2009

Canadian Arthritis Network to host 2009 Annual Scientific Conference in Vancouver

People with arthritis and leading Canadian and international researchers will share the stage under the theme "Decoding Arthritis - A Joint Effort" when the Canadian Arthritis Network (CAN) hosts its 2009 Annual Scientific Conference beginning tonight, in Vancouver, BC.

19 Nov 2009

VisEn Medical launches two new agents for imaging quantification

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.

19 Nov 2009

Study: EP4 agonist may reduce gastric bleeding and inflammation

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding.

19 Nov 2009

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).

19 Nov 2009

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has entered into an agreement with GeneNews (TSX: GEN), of Toronto, Canada, for exclusive rights to market GeneNews’ ColonSentry™, a proprietary blood test for colorectal cancer, in the states of New York and New Jersey.

18 Nov 2009

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Arrayit Corporation announced today that the new High Throughput Biology Center at Johns Hopkins University School of Medicine in Baltimore Maryland purchased Arrayit's proprietary technology to create a Human Proteome Chip to discover biomarkers for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis (first identified by Dr. Zhu), lupus, and others.

18 Nov 2009

Previous flu infections can reduce the severity of H1N1

Researchers at the La Jolla Institute for Allergy & Immunology have found that previous influenza infections may provide at least some level of immunity to the H1N1 "swine" flu. "The question we asked was, "Is the swine flu more like the seasonal flu or like a totally new strain of influenza where there would be no immunity?," said Alessandro Sette, Ph.D., an internationally recognized vaccine expert and director of the La Jolla Institute's Center for Infectious Disease.

18 Nov 2009

FDA approves Qutenza, a pain relief product for patients who suffer from PHN

The Food and Drug Administration (FDA) has approved the approval of Qutenza (capsaicin) 8% patch, a medicated skin patch that relieves the pain of post-herpetic neuralgia (PHN), a serious complication that can occur after a bout with shingles.

18 Nov 2009

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Smoothie Factory supports Chronic Disease Fund’s mission with holiday fundraising program

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Canadians with chronic neck and back pain now have access to top spinal care

Current, older generation is more prone to hip and pelvic fractures

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Health Heritage: New website for maintaining family's health history

Vitamin D: A multi-purpose nutrient for overall health

Morbid obesity among people with diabetes is increasing at a very alarming rate, says kidney expert

NAPRELAN Dose Card launched by Victory Pharma

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

Canadian Arthritis Network to host 2009 Annual Scientific Conference in Vancouver

VisEn Medical launches two new agents for imaging quantification

Study: EP4 agonist may reduce gastric bleeding and inflammation

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Previous flu infections can reduce the severity of H1N1

FDA approves Qutenza, a pain relief product for patients who suffer from PHN

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in